NCT01604213View on ClinicalTrials.gov

Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Type 2 Diabetes MellitusIschemic Heart Disease
Interventions
DRUG

Metformin plus vildagliptin

Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary

DRUG

Metformin only

Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated

Trial Locations (1)

52621

Sheba Medical Center, Cardiac Rehabilitation Institute, Tel Litwinsky

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV

NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease | Biotech Hunter | Biotech Hunter